Fig 2: CD8+ TILs are major antitumor effector cells in CTCL.a Pie charts show the distribution of TCRαβ clonotypes of conventional CD4+ T cells (Tconvs), CD4+ regulatory T cells (Tregs) and CD8+ T cells from the 10× Genomics dataset based on clonal frequency. T cells with TCR clonotype frequency ≥3 are defined as clonally expanded T cells. b UMAP plots show all reactive CD8+ TILs from the 10× Genomics dataset after re-clustering with the expression of canonical exhaustion markers, including PDCD1, HAVCR2, CTLA4, LAG3, TIGIT and TCF7. The color scale represents normalized expression. Gray to red: low to high expression. c (Left) Pie charts show the distribution of TCRαβ clonotypes of reactive CD8+ TILs in the TCyEM and TCM groups based on clonal frequency. T cells with TCR clonotype frequency ≥3 are defined as clonally expanded T cells. (Right) Bar plot shows the proportion of Exlow and Exhigh CD8+ TILs in the TCyEM and TCM groups. ***p < 0.001. P values were calculated using Pearson’s chi-square test. P = 2.20 × 10−16. d Violin plots show the expression levels of MHC-I molecules, including HLA-A, HLA-B, HLA-C, HLA-E and HLA-F, as well as LGALS9 in malignant T cells in the TCyEM and TCM groups (log2 fold-change >0.5, ***p < 0.001). P = 0 (all genes). e Representative immunofluorescence staining of TOX (green) and LGALS9 (red) on paraffin-embedded tissue samples from representative TCyEM (upper panel) and TCM (bottom panel) patients. DAPI (blue) was used to visualize cell nuclei. Scale bar = 50 μm. Results are representative of three different samples. Source data for (c) are provided in the Source Data file.

Fig 3: Flow cytometry histograms of TIGIT level in peripheral blood of preoperative (A and B) versus postoperative (C and D) PBC patients.

Fig 4: Representative immunofluorescence microscopic images of TIGIT, CD3, and CD56 in BC tissues and adjacent tissues.

Fig 5: TIGIT expression in pan-cancer tissues and Kaplan-Meier survival curves of BC patients. (A) TIGIT level in pan-cancer tissues and normal tissues. (B) TIGIT expression in invasive BC tumor tissue (TT) versus adjacent normal tissue (NT). (C) Relationship between TIGIT expression and BC stage. (D and E) Recurrence-free survival (RFS) and overall survival (OS) of BC patients with high-level TIGIT versus low-level TIGIT, respectively.